10 recruiting, 7 completed, 6 not yet recruiting, 2 active not recruiting. 13 Not applicable, 2 Phase 2, 2 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 13 | Completed 6, Recruiting 4, Not yet recruiting 3 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 2 | Recruiting 2 |
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Unknown 1 |
Follow GLP-1: new trials by email Literature Review of GLP-1 trials Research Report on GLP-1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics Acute Ethanol Dose - GLP-1, Alcohol | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 5 | 2026-10-01 | 2026-08-11 |
| Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis Mazdutide injection - Cirrhosis, Portal Hypertension | Not applicable | Not yet recruiting | The Second Affiliated Hospital of Chongqing Medical University | 50 | 2026-09-01 | 2026-09-01 |
| Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy. GLP-1 Stop for 1 week, GLP-1 non stop - GLP-1 | Phase 3 | Recruiting | Fu Jen Catholic University Hospital | 140 | 2026-06-01 | 2026-09-03 |
| Discontinuation Recommendations for GLP-1 Receptor Agonists Prior to Colonoscopy GLP-1 not stop for 1 week, GLP-1 stop for 1 week - GLP-1 | Not applicable | Recruiting | Fu Jen Catholic University Hospital | 240 | 2026-06-01 | 2026-09-03 |
| Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass Type 2 Diabetes, Obesity | Recruiting | University of Alberta | 50 | 2026-05-15 | 2026-07-17 | |
| Slowly Digestible Carbohydrates for GLP-1 Secretion Maltodextrin (Placebo), Raw Corn Starch - Blood Glucose, GLP-1 | Not applicable | Recruiting | Purdue University | 19 | 2026-05-01 | 2026-05-07 |
| Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer GLP-1 receptor agonist, Total neoadjuvant therapy (TNT) - Rectal Cancer Patients, Obesity &Amp; Overweight | Phase 2 | Not yet recruiting | St. James's Hospital, Ireland | 42 | 2026-04-01 | 2026-01-02 |
| Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity Dry Eye Disease (DED), Diabete Mellitus | Recruiting | Attikon Hospital | 100 | 2026-03-01 | 2026-06-02 | |
| GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women Body Composition, Muscle Function | Active not recruiting | University of Kansas Medical Center | 50 | 2026-02-12 | 2026-08-07 | |
| A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs AG1 - Nutritional Supplement, Placebo - Nutrition Intake, Nutrition Status | Not applicable | Recruiting | Athletic Greens International | 120 | 2026-02-01 | 2026-02-27 |
| Impact of Probiotic (UltraFlora® Triplebiotic) on Weight Evolution on People After Discontinuation of GLP-1 Treatment. UltraFlora® Triplebiotic, Placebo - Adults, GLP-1 | Not applicable | Not yet recruiting | Metagenics, Inc. | 128 | 2025-11-01 | 2025-10-06 |
| Impact of Multivitamin (PhytoMulti®) and a Probiotic (UltraFlora® Balance Probiotic) on Gut Health of People Taking GLP-1 Medication Multivitamin and a Probiotic - GLP-1, Adults | Not applicable | Not yet recruiting | Metagenics, Inc. | 100 | 2025-11-01 | 2025-08-19 |
| Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults Intervention: Dietary Supplement with Plant Extracts, Placebo - GLP-1, Obesity &Amp; Overweight | Not applicable | Completed | FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation | 40 | 2025-10-24 | 2026-06-15 |
| The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight GLP-1, Nutrition | Recruiting | Medical University of Warsaw | 100 | 2025-08-15 | 2025-12-08 | |
| Evaluation of a Nutritional Intervention With Dietary Supplements in People Who Have Recently Lost Weight: Effects on Body Composition, Emotional Health, and Gut Microbiota Metabolaid®-based nutraceutical formulation, Placebo capsules - GLP-1, Weight Loss Trajectory | Not applicable | Completed | University of Alicante | 70 | 2025-07-01 | 2026-10-05 |
| Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity GLP-1, CBTe Group Therapy - Binge Eating Disorder Associated With Obesity, Binge Eating Disorder | Recruiting | Haukeland University Hospital | 80 | 2025-07-01 | 2025-09-15 | |
| Impact of GLP-1 Receptor Agonists on Patients With IPMN GLP1 receptor agonist - IPMN, IPMN, Pancreatic | Not yet recruiting | Hôpital Fribourgeois | 30 | 2025-05-31 | 2025-06-11 | |
| A Trial to Assess Gastrointestinal Responses to Dietary Fibers in Adults Using Weight Loss Medications High Fiber Bar with Inulin, High Fiber bar with Fiber Blend, High Fiber Bar with Resistant Starch type 4 - Gastrointestinal Symptoms, Weight Loss | Not applicable | Completed | Midwest Center for Metabolic and Cardiovascular Research | 50 | 2025-05-29 | 2026-01-08 |
| Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study GB, Placebo - Blood Sugar; High, Overweight and Obesity | Not applicable | Completed | Lawry Han | 69 | 2025-01-07 | 2025-09-03 |
| MAINTAIN (Mucosal AblatIoN Therapy After INcretins) Gastric Fundal Mucosal Ablation (GFMA) - Obesity and Obesity-related Medical Conditions, Obesity and Overweight | Not applicable | Recruiting | Dr. Christopher McGowan | 20 | 2025-01-01 | 2025-03-21 |
Showing 20 of 26. Sign in to see all of them.
Obesity (7) · Overweight (5) · Diabetes Mellitus, Type 2 (4) · Diabetes Mellitus (3) · Insulin Resistance (2) · Weight Loss (2) · Binge-Eating Disorder (1) · Body-Weight Trajectory (1) · Corneal Diseases (1) · Depression (1) · Diabetic Retinopathy (1) · Dry Eye Syndromes (1) · Feeding and Eating Disorders (1) · Fibrosis (1) · Hyperglycemia (1)
Nutritional and Metabolic Diseases (12) · Pathological Conditions, Signs and Symptoms (11) · Body Weight (9) · Signs and Symptoms (9) · Glucose Metabolism Disorders (7) · Metabolic Diseases (7) · Nutrition Disorders (7) · Overnutrition (7) · Endocrine System Diseases (6) · Body Weight Changes (3) · Digestive System Diseases (3) · Diabetes Mellitus (2) · Eye Diseases (2) · Hyperinsulinism (2) · Mental Disorders (2)
Glucagon-Like Peptide 1 (2) · Ascorbic Acid (1) · Geritol (1) · Inulin (1) · Metformin (1) · Naltrexone (1) · Plant Extracts (1) · Sirolimus (1) · Starch (1) · maltodextrin (1) · mazdutide (1) · semaglutide (1) · trichlorosucrose (1)
Fu Jen Catholic University Hospital (2) · Metagenics, Inc. (2) · AgelessRx (1) · Anders Fink-Jensen, MD, DMSci (1) · Athletic Greens International (1) · Attikon Hospital (1) · Dr. Christopher McGowan (1) · FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation (1) · Haukeland University Hospital (1) · Hôpital Fribourgeois (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · Lawry Han (1) · Medical University of South Carolina (1) · Medical University of Warsaw (1) · Midwest Center for Metabolic and Cardiovascular Research (1)
United States (10) · Greece (2) · Taiwan (2) · Austria (1) · Canada (1) · Denmark (1) · Mexico (1) · Norway (1) · Poland (1) · Spain (1) · Switzerland (1)
Irfan Qureshi, MD (2) · Mieke Van Den Driessche, PhD (2) · Anders Fink-Jensen, MD (1) · Christopher McGowan, MD, MSCR (1) · Christopher Wolla, M.D. (1) · Daniel Weghuber, Prim. Univ. Prof. Dr. (1) · Heather Barkholtz, PhD (1) · Johanna Finkle, MD (1) · Kevin C Maki, PhD (1) · Lawry Han, PhD (1) · Michael Chen, MD (1) · Michael Kelly, MB BAO BCH PHD FRCSI (1) · Stefanie Morgan, PhD (1)
PMID 32923389, PMID 33567185, PMID 35565381, PMID 36294412, PMID 36720576, PMID 37085291, PMID 38182527, PMID 38888262, PMID 38893212, PMID 38967919, PMID 39093546, PMID 40140925, PMID 40285503, PMID 40437949, PMID 40907790, PMID 41335431, PMID 41806363, PMID 42715243
2025 (1)